Biotechnology company ZandCell LLC reported on Tuesday the availability of a fast, reliable and affordable COVID-19 saliva based rapid antigen test kit to be used in airports, governments, states, hospitals, sports events and for healthcare workers.
According to ZandCell, its COVID-19 Rapid Antigen Test rapidly tests to qualitatively detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.
The saliva-based ZandCell COVID-19 Rapid Antigen Test is now available in large quantities and can quickly and effectively test patients for the infectious virus and provide immediate results within three to ten minutes.
ZandCell COVID-19 Rapid Antigen Test was CE certified on 11 September and will be available in the US upon EUA FDA approval.
CStone Pharmaceuticals' sugemalimab granted new indication by UK MHRA
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
Beyfortus study shows sustained reduction in infant RSV hospitalisations across two seasons
AstraZeneca reports positive Phase III results for BREZTRI in uncontrolled asthma
Akeso's AK139 Phase II clinical trials approved in China
Median Technologies secures FDA clearance for AI lung cancer screening software
Insilico Medicine names new vice president, Clinical Development – Oncology
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Guerbet's contrast agent Elucirem approved by European Commission in children from birth